Clinical Trial Update: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies [Phase 1]

View source ↗

Summary

The Phase 1 study evaluating AB308 in combination with AB122 in participants with advanced malignancies has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Diffuse Large B-cell Lymphoma
• Esophageal Cancer
• Gastric Cancer
• Melanoma
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Non-small Cell Lung Cancer

Drugs mentioned

• AB122
• AB308

Snippet

Sponsor: Arcus Biosciences, Inc. | Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: COMPLETED